Related Experiment Videos
Trastuzumab therapy for the metastatic patient: does the primary match?
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2018
Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2017
Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis.
Annals of oncology : official journal of the European Society for Medical Oncology·2014
Targeting basal-like breast cancers.
Current drug targets·2012
Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer.
British journal of cancer·2012
Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Atezolizumab with or without tiragolumab in unresectable esophageal squamous cell carcinoma following definitive concurrent chemoradiotherapy (SKYSCRAPER-07): a randomised, phase III study.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER).
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Eight-year outcomes of testosterone suppression plus enzalutamide or a non-steroidal anti-androgen for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Lipid Metabolism in Regulatory T Cells in Health and Disease.
Journal of inflammation research·2026
The diagnosis and management of primary mediastinal B-cell lymphoma: A British Society for Haematology guideline.
British journal of haematology·2026
Anakinra Prophylaxis for Recurrent Severe ICANS Associated With Tarlatamab in Small Cell Lung Cancer: Case Report.
JTO clinical and research reports·2026
Immunotherapy for Glioma: A compartmental framework for resistance and rational combination design.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
B-cells in breast cancer: current insights and challenges.
Frontiers in oncology·2026